NCT06007794 Correlation Between Ultrasound-assessed Quadriceps Muscle Mass and Baseline Whole-body Densitometry Muscle Index in the Post-cancer Population (JUMP Research II)
| NCT ID | NCT06007794 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 55 participants |
| Start Date | 2025-02-10 |
| Primary Completion | 2029-02-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 55 participants in total. It began in 2025-02-10 with a primary completion date of 2029-02-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Therapeutic advances in oncology have transformed the prognosis of cancer patients, placing a significant number of them either in a context of recovery or in prolonged remission close to a chronic disease. Thus, the reconquest of a life after cancer becomes possible but raises many challenges for the patient, his entourage, the medical profession and our society. One of the major challenges is the detection and management of treatment side effects for all patients. In addition to the standard organic assessment (glycaemia, creatinine, liver test, blood count), we are mainly interested in muscle deconditioning and cognitive impairment, which are particularly disturbed in these populations. After the evaluation day, patients are referred to the most appropriate structures (Adapted physical activity, sports for health, and rehabilitation at Henry Gabriel Hospital). JUMP research is part of axis 2 of the 2021-2030 cancer plan: "Limiting sequelae and improving quality of life", through sheets 1 (research) / 6 (access and quality) / 7 (prevention). This leads to the concrete implementation on the territory of adapted care channels in the city: medical structure, physiotherapy, Adapted Physical Activity (APA) structures, associative structures; which makes it possible to develop and strengthen the city-hospital link. Finally, it allows the patient to take ownership and get involved in the project, allowing in the future to make them truly active in they care and to advise and motivate their peers. This non-interventional research is classified as "research involving human subjects", class 3 . The objective of this research is to evaluate the impact of cancer on the musculoskeletal system and to test ultrasound as a clinical examination for the detection of sarcopenia in this population.
Eligibility Criteria
Inclusion Criteria: * Age : 18 to 74 years * localization of the primitive: breast, lung, melanoma, testicle, bladder, kidney, ovary, colon and pancreas, hemopathy * patient who benefited from the post-cancer assessment day Exclusion Criteria: * Active cancer (relapse or new cancer) * Pregnant or breastfeeding women * Major cognitive impairment making comprehension and exercise difficult * Amputation of both lower limbs (for ultrasound) * Difficulty understanding oral and written French * Adults under legal protection (guardianship, curatorship or safeguard of justice)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06007794 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 74 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06007794 currently recruiting?
Yes, NCT06007794 is actively recruiting participants. Contact the research team at Cyrille.confavreux@chu-lyon.fr for enrollment information.
Where is the NCT06007794 trial being conducted?
This trial is being conducted at Pierre-Bénite, France.
Who is sponsoring the NCT06007794 clinical trial?
NCT06007794 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 55 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.